Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine ...

The MarketWatch News Department was not involved in the creation of this content. Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene ...

Trodelvy reduced risk of disease progression or death versus chemotherapy in patients with previously untreated metastatic triple-negative breast cancer. Treatment with Trodelvy (Sacituzumab govitecan ...

Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer. The biopharma evaluated the Bristol Myers Squibb-partnered ...

I am sure you are aware of the distorted negative advertising regarding Bill 9. I hope this will not deter Maui County Council members from taking this bold step to end the lack of affordable housing ...

Even though the function of single phase and three phase relays are quite similar, their applications can vary significantly. This is primarily due to the characteristics of three phase power circuits ...

Pattern of granulocyte colony stimulating growth factors (G-CSGF) usage in patients treated with sacituzumab govitecan: A real world multicenter study using the TriNetX database. This is an ASCO ...

HERTHENA-Breast03: A phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...